Experimental CAR t therapy aims to tame multiple sclerosis
NCT ID NCT07303790
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This early study is testing a new treatment called GC012F, which uses a patient's own immune cells (CAR T cells) to target multiple sclerosis. The main goal is to see if it is safe and tolerable for people with MS. Only 9 participants will be enrolled, and they will be monitored for side effects for up to 15 years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITINGHubei, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.